Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Up 39.39% in one week

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Mar 01, 2024 2:00pm

27 Views

Post# 35909851

RE:RE:RE:Re: Up 39.39% in one week

What happened is called life. Life is what hits you after you develop your plans and expectations. COVID dealt historic unpredictability to the market. How much did demand change and how much was inventory building by the supply chain? Multi-decade high inflation also dealt unpreditatability and hit the consumer. The central bankers had to crush inflation with the most rapid interest rate hiking cycle in memory. Then there was the reorganization of CZO's major client - a freak event that has never happened. We haven't been living in linear times for this company that are easily predictable. We've been living in a world of profound shocks. CZO has had to adjust its development plans through lab closures, and client reorganization and thanks to the base business and Gilles conservative nature cash reserves were built up. The increasing needs of the pipeline as CZO hits expected milestones and the drawdown of cash reserves due to unpredictable events make planning ahead important. CZO's recent news release outlining its pipline is bigger than we expected. As CZO reaches commercial-scale production for PGX and the point of deal making having AEZS's capital and internal capabilities can put it in a position of strength as deals are nailed down. Clinical trials for CZO are also potentially advancing from avenanthramide, to fibrosis, to wound healing. Capital and additional human resourses help address the coming need. The biotech market also coughed up the chance to acquire biotech assets below cash. A rare opportunity. Its AIM Biologicals lead program alone addresses a U$2.5 billion market in a differentiated manner. It could be bigger than CZO given it is an expandable platform and it also provides diversification.

Tencents wrote: There seems to be a significant inconsistency in interpretations
the ceo stated in 2022/2023 financial updates
1. Significant growth in base business sales is expected to continue
2. the cash on hand is sufficient to bring current pipeline objectives to fruition

so what is the need to merge with anyone
it can only be that 1 and 2 were poorly evaluated and there was a need to find a way out